Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhelion Life SciencesTRUFF +11.21% Buyback Yield % is 0.00 as of Aug. 05, 2026. The stock has 3 warning signs investors should review. Among 276 Drug Manufacturers companies, Rhelion Life Sciences ranks worse than 362318.48% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Rhelion Life Sciences Buyback Yield % Related Terms
Rhelion Life Sciences Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Rhelion Life Sciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhelion Life Sciences (TRUFF) has a Buyback Yield % of 0.00 as of Aug. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Rhelion Life Sciences and its competitors. According to the industry distribution chart, Rhelion Life Sciences ranks #999999 out of 276 companies in the Drug Manufacturers industry.
Is Rhelion Life Sciences' Buyback Yield % too high?
Rhelion Life Sciences' current Buyback Yield % is 0.00. Based on the distribution chart, Rhelion Life Sciences ranks #999999 out of 276 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Rhelion Life Sciences' Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Rhelion Life Sciences ranks #999999 out of 276 companies for Buyback Yield %. This places Rhelion Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Rhelion Life Sciences and its competitors. Rhelion Life Sciences's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (TRUFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 24% above its estimated fair value. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Rhelion Life Sciences (TRUFF), the current Buyback Yield % is 0.00 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRUFF has been successfully added to your 
